| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
Lebert JM, Lester R, Powell E, et al. Advances in the systemic treatment of triple-negative breast cancer [J]. Curr Oncol, 2018, 25(1): 142-150.
|
| [3] |
Elghazaly H, Rugo HS, Azim HA, et al. Breast-gynaecological & immuno-oncology international cancer conference (BGICC) consensus and recommendations for the management of triple-negative breast cancer [J]. Cancers (Basel), 2021, 13(9): 2262.
|
| [4] |
Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial [J]. Lancet, 2020, 396(10265): 1817-1828.
|
| [5] |
Perez-Garcia J, Soberino J, Racca F, et al. Atezolizumab in the treatment of metastatic triple-negative breast cancer [J]. Expert Opin Biol Ther, 2020, 20(9): 981-989.
|
| [6] |
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer [J]. N Engl J Med, 2020, 382(9): 810-821.
|
| [7] |
Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study [J]. Ann Oncol, 2022, 33(5)：534-543.
|
| [8] |
Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies [J]. Cancer Cell, 2019，35(3)：428-440.
|
| [9] |
Wu Y, Chen W, Xu ZP, et al. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition [J]. Front Immunol, 2019, 10：2022.
|
| [10] |
Seto T, Sam D, Pan M. Mechanisms of primary and secondary resistance to immune checkpoint inhibitors in cancer [J]. Med Sci (Basel), 2019, 7(2): 14.
|
| [11] |
Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy [J]. Lancet Oncol, 2018, 19(1): 40-50.
|
| [12] |
Polonia A, Pinto R, Cameselle-Teijeiro JF, et al. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer [J]. J Clin Pathol, 2017, 70(10): 860-867.
|
| [13] |
Szekely B, Bossuyt V, Li X, et al. Immunological differences between primary and metastatic breast cancer [J]. Ann Oncol, 2018, 29(11): 2232-2239.
|
| [14] |
Zitvogel L, Galluzzi L, Smyth MJ, et al. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance [J]. Immunity, 2013, 39(1): 74-88.
|
| [15] |
Fournier C, Vargas TR, Martin T, et al. Immunotherapeutic properties of chemotherapy [J]. Curr Opin Pharmacol, 2017, 35: 83-88.
|
| [16] |
Liu J, Blake SJ, Yong MC, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease [J]. Cancer Discov, 2016, 6(12): 1382-1399.
|
| [17] |
Hutchinson KE, Yost SE, Chang CW, et al. Comprehensive profiling of poor-risk paired primary and recurrent triple-negative breast cancers reveals immune phenotype shifts [J]. Clin Cancer Res，2020，26(3)：657-668.
|
| [18] |
Bourgeois-Daigneault MC, Roy DG, Aitken AS, et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy [J]. Sci Transl Med, 2018, 10(422): eaao1641.
|
| [19] |
Brockwell NK, Owen KL, Zanker D, et al. Neoadjuvant interferons: critical for effective PD-1-based immunotherapy in TNBC [J]. Cancer Immunol Res, 2017, 5(10): 871-884.
|
| [20] |
Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study [J]. Breast Cancer Res Treat, 2018, 167(3): 671-686.
|
| [21] |
Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer a phase 1 study [J]. JAMA Oncol, 2019, 5(1): 74-82.
|
| [22] |
Cortes J, Lipatov O, Im SA, et al. KEYNOTE-119: Phase Ⅲ study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC) [J]. Ann Oncol, 2019, 30：859.
|
| [23] |
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer [J]. N Engl J Med, 2018, 379(22): 2108-2121.
|
| [24] |
Schmid P, Salgado R, Park YH, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study [J]. Ann Oncol, 2020, 31(5): 569-581.
|
| [25] |
Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial [J]. JAMA Oncol, 2020, 6(5): 676-684.
|
| [26] |
Loibl S, Untch M, Burchardi N, et al. A randomised phase Ⅱ study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study [J]. Ann Oncol, 2019, 30(8): 1279-1288.
|
| [27] |
Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial [J]. Lancet, 2020, 396(10257): 1090-1100.
|
| [28] |
Foldi J, Silber A, Reisenbichler E, et al. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer [J]. NPJ Breast Cancer, 2021, 7(1): 9.
|
| [29] |
Nahleh ZA, Barlow WE, Hayes DF, et al. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer [J]. Breast Cancer Res Treat, 2016, 158(3): 485-495.
|
| [30] |
Geyer CE, Loibl S, Rastogi P, et al. NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase Ⅲ clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo [J]. J Clin Oncol, 2018, 36(15_suppl): TPS603-TPS603.
|
| [31] |
Domchek SM, Postel-Vinay S, Im SA, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study [J]. Lancet Oncol, 2020, 21(9): 1155-1164.
|
| [32] |
Quintela-Fandino M, Holgado E, Manso L, et al. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial [J]. Breast Cancer Res, 2020, 22(1): 124.
|
| [33] |
Pascual J, Turner NC. Targeting the PI3-kinase pathway in triple-negative breast cancer [J]. Ann Oncol, 2019, 30(7): 1051-1060.
|
| [34] |
Oliveira M, Saura C, Nuciforo P, et al. FAIRLANE, a double-blind placebo-controlled randomized phase Ⅱ trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer [J]. Ann Oncol, 2019, 30(8): 1289-1297.
|
| [35] |
Brockwell NK, Parker BS. Tumor inherent interferons: Impact on immune reactivity and immunotherapy [J]. Cytokine, 2019, 118: 42-47.
|
| [36] |
McLaughlin M, Patin EC, Pedersen M, et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy [J]. Nat Rev Cancer, 2020, 20(4): 203-217.
|
| [37] |
Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity [J]. Nat Commun, 2017, 8: 15 618.
|
| [38] |
Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial [J]. Nat Med, 2019, 25(6): 920-928.
|
| [39] |
Aguilera TA, Elghonaimy EA, Shehade H, et al. Induced tumor heterogeneity reveals factors informing radiation and immunotherapy combinations [J]. Clin Cancer Res, 2020, 26(12): 2972-2985.
|
| [40] |
Rahimi A, Thomas K, Spangler A, et al. Preliminary results of a phase 1 dose-escalation trial for early-stage breast cancer using 5-fraction stereotactic body radiation therapy for partial-breast irradiation [J]. Int J Radiat Oncol, 2017, 98(1): 196.
|
| [41] |
Takada M, Toi M. Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes [J]. Int J Clin Oncol, 2019, 24(6): 608-613.
|
| [42] |
McArthur HL, Diab A, Page DB, et al. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling [J]. Clin Cancer Res, 2016, 22(23): 5729-5737.
|
| [43] |
Chen J, Qian W, Mu F, et al. The future of cryoablation: An abscopal effect [J]. Cryobiology, 2020, 97: 1-4.
|
| [44] |
Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603 (Alliance) [J]. J Clin Oncol, 2015, 33(1): 13-21.
|
| [45] |
Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer [J]. N Engl J Med, 2022, 386(6)：556-567.
|
| [46] |
Shah M, Osgood CL, Amatya AK, et al. FDA approval summary: pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early-stage triple negative breast cancer [J]. Clin Cancer Res, 2022，28(24)：5249-5253.
|
| [47] |
Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy [J]. N Engl J Med, 2017, 376(22): 2147-2159.
|
| [48] |
Pandy JGP, Balolong-Garcia JC, Cruz-Ordinario MVB, et al. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review [J]. BMC Cancer, 2019, 19(1): 1065.
|
| [49] |
Lynce F, Nunes R. Role of platinums in triple-negative breast cancer [J]. Curr Oncol Rep, 2021, 23(5): 50.
|
| [50] |
Miles D, Gligorov J, Andre F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase Ⅲ trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer [J]. Ann Oncol, 2021, 32(8)：994-1004.
|
| [51] |
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J]. Lancet, 2014, 384(9938): 164-172.
|
| [52] |
Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy [J]. Lancet Oncol，2018, 19(1): 40-50.
|
| [53] |
Barroso-Sousa R, Jain E, Cohen O, et al. Prevalence and mutational determinants of high tumor mutation burden in breast cancer [J]. Ann Oncol, 2020, 31(3): 387-394.
|